Dead-Sea climatotherapy versus other modalities of treatment for psoriasis: comparative cost-effectiveness

被引：27
|
作者：
Shani, J
Harari, M [1 ]
Hristakieva, E
Seidl, V
Bar-Giyora, J
机构：
[1] Deutsch Med Zentrum Clin, Lot Hotel, MOR, IL-86930 Ein Bokek, Israel
[2] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel
[3] Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Jerusalem, Israel
来源：
INTERNATIONAL JOURNAL OF DERMATOLOGY | 1999年 / 38卷 / 04期
关键词：
D O I：
10.1046/j.1365-4362.1999.00583.x
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
[No abstract available]
引用
收藏
页码：252 / 262
页数：11
相关论文
共 50 条
  • [41] Cost-effectiveness analysis of chronic mechanical back pain treatment modalities
    Baser, Ozgun Cakmak
    Ay, Saime
    Evcik, Deniz
    TURKISH JOURNAL OF PHYSICAL MEDICINE AND REHABILITATION, 2020, 66 (04): : 413 - 422
  • [42] The Cost-Effectiveness of Treatment Modalities for Ureteral Stones: A National Comprehensive Study
    Siu, Justin Ji-Yuen
    Chen, Huey-Yi
    Liao, Po-Chi
    Chiang, Jen-Huai
    Chang, Chao-Hsiang
    Chen, Yung-Hsiang
    Chen, Wen-Chi
    INQUIRY-THE JOURNAL OF HEALTH CARE ORGANIZATION PROVISION AND FINANCING, 2016, 53
  • [43] Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany
    Augustin, M.
    McBride, D.
    Gilloteau, I.
    O'Neill, C.
    Neidhardt, K.
    Graham, C. N.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (12) : 2191 - 2199
  • [44] COST-EFFECTIVENESS OF SECUKINUMAB AS FIRST BIOLOGIC TREATMENT FOR PSORIASIS COMPARED WITH INITIATING OTHER BIOLOGIC THERAPY IN GERMANY
    Augustin, M.
    Krieger, T.
    McBride, D.
    Graham, C. N.
    Melzer, N.
    Kneidl, J.
    Neidhardt, K.
    VALUE IN HEALTH, 2016, 19 (07) : A568 - A569
  • [45] Effectiveness and cost-effectiveness of four treatment modalities for substance disorders: A propensity score analysis
    Mojtabai, R
    Zivin, JG
    HEALTH SERVICES RESEARCH, 2003, 38 (01) : 233 - 259
  • [46] COST-EFFECTIVENESS OF SECUKINUMAB IN MODERATE TO SEVERE PSORIASIS COMPARED WITH OTHER BIOLOGICS IN GERMANY
    Graham, C. N.
    McBride, D.
    Miles, L.
    Gilloteau, I
    O'Neill, C. B.
    Neidhardt, K.
    Augustin, M.
    VALUE IN HEALTH, 2017, 20 (05) : A157 - A157
  • [47] Clinical evaluation of a more rapid and sensitive Psoriasis Assessment Severity Score (PASS), and its comparison with the classic method of Psoriasis Area and Severity Index (PASI), before and after climatotherapy at the Dead-Sea
    Harari, M
    Shani, J
    Hristakieva, E
    Stanimirovic, A
    Seidl, W
    Burdo, A
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2000, 39 (12) : 913 - 918
  • [48] Cost-effectiveness of to bradex versus zylet for the treatment of blepharokeratoconjunctivitis
    Rahman, A.
    Waycaster, C.
    Smith, D.
    VALUE IN HEALTH, 2008, 11 (03) : A290 - A290
  • [49] COMPARATIVE COST-EFFECTIVENESS MODELS FOR THE TREATMENT OF MULTIPLE MYELOMA
    Cooper, Keith
    Picot, Joanna
    Bryant, Jackie
    Clegg, Andrew
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2014, 30 (01) : 90 - 97
  • [50] EFFECT OF TREATMENT SWITCH ON THE COST-EFFECTIVENESS OF BIOLOGICS IN PSORIASIS IN PERU AND COLOMBIA
    Alandete, J. C.
    VALUE IN HEALTH, 2011, 14 (03) : A58 - A58
12345